Thomas Gaudelet

Paul Scherer, Alison Pouplin, Alice Del Vecchio et al.

Active learning (AL) is a sub-field of ML focused on the development of methods to iteratively and economically acquire data by strategically querying new data points that are the most useful for a particular task. Here, we introduce PyRelationAL, an open source library for AL research. We describe a modular toolkit based around a two step design methodology for composing pool-based active learning strategies applicable to both single-acquisition and batch-acquisition strategies. This framework allows for the mathematical and practical specification of a broad number of existing and novel strategies under a consistent programming model and abstraction. Furthermore, we incorporate datasets and active learning tasks applicable to them to simplify comparative evaluation and benchmarking, along with an initial group of benchmarks across datasets included in this library. The toolkit is compatible with existing ML frameworks. PyRelationAL is maintained using modern software engineering practices -- with an inclusive contributor code of conduct -- to promote long term library quality and utilisation. PyRelationAL is available under a permissive Apache licence on PyPi and at https://github.com/RelationRx/pyrelational.

Peter St. John, Dejun Lin, Polina Binder et al.

Artificial Intelligence models encoding biology and chemistry are opening new routes to high-throughput and high-quality in-silico drug development. However, their training increasingly relies on computational scale, with recent protein language models (pLM) training on hundreds of graphical processing units (GPUs). We introduce the BioNeMo Framework to facilitate the training of computational biology and chemistry AI models across hundreds of GPUs. Its modular design allows the integration of individual components, such as data loaders, into existing workflows and is open to community contributions. We detail technical features of the BioNeMo Framework through use cases such as pLM pre-training and fine-tuning. On 256 NVIDIA A100s, BioNeMo Framework trains a three billion parameter BERT-based pLM on over one trillion tokens in 4.2 days. The BioNeMo Framework is open-source and free for everyone to use.

Thomas Gaudelet, Alice Del Vecchio, Eli M Carrami et al.

Interventions play a pivotal role in the study of complex biological systems. In drug discovery, genetic interventions (such as CRISPR base editing) have become central to both identifying potential therapeutic targets and understanding a drug's mechanism of action. With the advancement of CRISPR and the proliferation of genome-scale analyses such as transcriptomics, a new challenge is to navigate the vast combinatorial space of concurrent genetic interventions. Addressing this, our work concentrates on estimating the effects of pairwise genetic combinations on the cellular transcriptome. We introduce two novel contributions: Salt, a biologically-inspired baseline that posits the mostly additive nature of combination effects, and Peper, a deep learning model that extends Salt's additive assumption to achieve unprecedented accuracy. Our comprehensive comparison against existing state-of-the-art methods, grounded in diverse metrics, and our out-of-distribution analysis highlight the limitations of current models in realistic settings. This analysis underscores the necessity for improved modelling techniques and data acquisition strategies, paving the way for more effective exploration of genetic intervention effects.

Luka Kovačević, Thomas Gaudelet, James Opzoomer et al.

Despite substantial efforts, deep learning has not yet delivered a transformative impact on elucidating regulatory biology, particularly in the realm of predicting gene expression profiles. Here, we argue that genuine "foundation models" of regulatory biology will remain out of reach unless guided by frameworks that integrate mechanistic insight with principled experimental design. We present one such ground-up, semi-mechanistic framework that unifies perturbation-based experimental designs across both in vitro and in vivo CRISPR screens, accounting for differentiating and non-differentiating cellular systems. By revealing previously unrecognised assumptions in published machine learning methods, our approach clarifies links with popular techniques such as variational autoencoders and structural causal models. In practice, this framework suggests a modified loss function that we demonstrate can improve predictive performance, and further suggests an error analysis that informs batching strategies. Ultimately, since cellular regulation emerges from innumerable interactions amongst largely uncharted molecular components, we contend that systems-level understanding cannot be achieved through structural biology alone. Instead, we argue that real progress will require a first-principles perspective on how experiments capture biological phenomena, how data are generated, and how these processes can be reflected in more faithful modelling architectures.

Paul Bertin, Jarrid Rector-Brooks, Deepak Sharma et al.

For large libraries of small molecules, exhaustive combinatorial chemical screens become infeasible to perform when considering a range of disease models, assay conditions, and dose ranges. Deep learning models have achieved state of the art results in silico for the prediction of synergy scores. However, databases of drug combinations are biased towards synergistic agents and these results do not necessarily generalise out of distribution. We employ a sequential model optimization search utilising a deep learning model to quickly discover synergistic drug combinations active against a cancer cell line, requiring substantially less screening than an exhaustive evaluation. Our small scale wet lab experiments only account for evaluation of ~5% of the total search space. After only 3 rounds of ML-guided in vitro experimentation (including a calibration round), we find that the set of drug pairs queried is enriched for highly synergistic combinations; two additional rounds of ML-guided experiments were performed to ensure reproducibility of trends. Remarkably, we rediscover drug combinations later confirmed to be under study within clinical trials. Moreover, we find that drug embeddings generated using only structural information begin to reflect mechanisms of action. Prior in silico benchmarking suggests we can enrich search queries by a factor of ~5-10x for highly synergistic drug combinations by using sequential rounds of evaluation when compared to random selection, or by a factor of >3x when using a pretrained model selecting all drug combinations at a single time point.

Thomas Gaudelet, Ben Day, Arian R. Jamasb et al.

Graph Machine Learning (GML) is receiving growing interest within the pharmaceutical and biotechnology industries for its ability to model biomolecular structures, the functional relationships between them, and integrate multi-omic datasets - amongst other data types. Herein, we present a multidisciplinary academic-industrial review of the topic within the context of drug discovery and development. After introducing key terms and modelling approaches, we move chronologically through the drug development pipeline to identify and summarise work incorporating: target identification, design of small molecules and biologics, and drug repurposing. Whilst the field is still emerging, key milestones including repurposed drugs entering in vivo studies, suggest graph machine learning will become a modelling framework of choice within biomedical machine learning.